Advertisement

Topics

Search Results for "Xarelto Vs Pradaxa"

22:54 EST 6th February 2016 | BioPortfolio

Matching Channels

Rivaroxaban

Rivaroxaban is the most broadly indicated novel oral anticoagulant and is marketed under the brand name Xarelto®. To date, Xarelto has been approved for use in the following indications across t...

Matching News

Lawsuitsettlementnews.com Secures Large Capital for Xarelto and Pradaxa Funding

NEW ORLEANS, Dec. 16, 2015 /PRNewswire/ -- MT Services LLC, a Lawsuit Settlement News Reporting Company which operates lawsuitsettlementnews.com, announced today that they have secured large capi...

Baron & Budd Warns Patients of Potentially Misleading Xarelto and Pradaxa Ads

The national law firm Baron & Budd is warning patients taking blood thinners about potentially misleading Xarelto and Pradaxa marketing material that may minimize the two bloo...

Location Set for First Xarelto Bellwether Trial, Says Lawsuitsettlementnews.com

NEW ORLEANS, Sept. 17, 2015 /PRNewswire/ -- MT Services LLC, a Lawsuit Settlement News Reporting Company which operates lawsuitsettlementnews.com, announced today that the location has been set f...

ESC: Eliquis Tied to Less Bleeding in Afib Versus Other NOACs (CME/CE)

(MedPage Today) -- Xarelto and Pradaxa turn in mixed results for clinically relevant non-major bleeding

New Xarelto Studies Show Link to Eye Hemorrhaging and Stomach Bleeding, Says Lawsuitsettlementnews.com

NEW ORLEANS, July 23, 2015 /PRNewswire/ -- MT Services LLC, a Lawsuit Settlement News Reporting Company which operates lawsuitsettlementnews.com, announced today that two new studies have shown a...

Legal-Bay Lawsuit Settlement Funding Reports Xarelto News: Bellwether Trial Dates Announced

PHILADELPHIA, Nov. 16, 2015 /PRNewswire/ -- Legal-Bay LLC, The Lawsuit Settlement Funding Company, reports today that the first bellwether trial dates in the Xarelto multidistrict litigation have...

Bayer backs safety of Xarelto after real-world data study

Around 96 in every 100 people treated with Bayer’s anticoagulant Xarelto do not experience any major bleeding, related side effects or death, according to the results of a major study into the use o...

FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa

The FDA has granted accelerated approval to Praxbind (idarucizumab) for use in patients who are taking the anticoagulant Pradaxa (dabigatran) during emergency situations when there is a need to revers...

Matching PubMed Articles

Waiting for the Antidote: The Journey of Idarucizumab as a Potential Specific Reversal Agent for Dabigatran (Pradaxa).

Waiting for the Antidote: The Journey of Idarucizumab as a Potential Specific Reversal Agent for Dabigatran (Pradaxa).

Pharmaceutical Approval Update.

Idarucizumab (Praxbind) to reverse the anticoagulant effects of dabigatran (Pradaxa); aripiprazole lauroxil (Aristada) for the treatment of schizophrenia; and insulin degludec injection (Tresiba) for ...

RECURRENT SUBRETINAL HEMORRHAGE ASSOCIATED WITH RIVAROXABAN ANTICOAGULATION.

To report a case of spontaneous recurrent significant subretinal hemorrhage in a patient on rivaroxaban (Xarelto).

Effects of Rivaroxaban Therapy on ROTEM Coagulation Parameters in Patients with Venous Thromboembolism.

Rivaroxaban (Xarelto) does not require routine coagulation monitoring; however, in certain clinical situations (overdose, drug accumulation, urgent surgery) measurement of its plasma concentration is ...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement